Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study is testing whether new drug combinations containing SKB500 are safe and effective for people with extensive-stage small cell lung cancer. The trial will enroll 80 adults to receive these experimental treatments and track how their cancer responds. Researchers will moni…

This is the first time a new drug called SKB518 is being tested in people. The main goal is to find a safe dose and see how the body handles it. The study will also check if the drug can help shrink tumors in adults with advanced solid cancers that have stopped responding to stan…

This study is testing whether a new drug called SKB264 works better than standard treatments for people with advanced HR+/HER2- breast cancer that has spread or returned after chemotherapy. Researchers will compare SKB264 against whatever treatment the doctor would normally choos…

This study is testing whether an experimental drug called A166 can help control advanced HER2-positive breast cancer that has spread and has stopped responding to certain other targeted treatments. About 40 adults who have already tried specific cancer drugs will receive A166 thr…

This is the first human study of an experimental cancer drug called SKB500. Researchers want to find out if it's safe, how the body processes it, and if it shows any signs of fighting cancer. The study will enroll 180 adults with advanced solid tumors that haven't responded to st…

This is the first study in people to test a new drug called SKB445 for patients with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs th…

This is the first study testing a new cancer drug called SKB571 in people. Researchers want to find the safest dose and see if it shows any early signs of fighting advanced solid tumors. The study will enroll about 138 adults whose cancer has spread or cannot be removed by surger…

This study is testing whether a new drug called SKB518 can help control lung cancer. About 192 adults with either non-small cell or small cell lung cancer will receive the drug until their cancer worsens or side effects become too severe. Researchers will measure how well the dru…

This study is testing whether a new drug called SKB264 works better than standard chemotherapy when combined with pembrolizumab immunotherapy for advanced non-small cell lung cancer. It's specifically for patients whose tumors test negative for PD-L1, a marker that often predicts…

This study is testing whether a new drug called SKB264 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread or returned and cannot be removed by surgery. It will involve 524 patients who have not yet received treatment for…

This study is testing if adding a new drug called SKB264 to the standard treatment (osimertinib) works better for people with a specific type of advanced lung cancer. It will involve 420 adults who have not yet received treatment for their advanced cancer. The main goal is to see…

This is the first human study of an experimental drug called SKB107 for people with advanced solid tumors that have spread to their bones. The main goal is to find a safe dose and see how the body handles the drug. It will enroll 90 adults whose cancer has progressed despite stan…

This study is testing whether a new drug called SKB264 works better than standard chemotherapy for people with advanced breast cancer that has stopped responding to hormone therapy. It will involve about 430 participants with HR+/HER2- breast cancer that has spread or returned. T…

This study is testing a new drug called SKB571 for people with advanced non-small cell lung cancer. The main goals are to see if the drug is safe and if it can shrink or control tumors. About 190 patients will receive the drug until their cancer gets worse or they have bad side e…

This study is testing a new drug called SKB315 for people with advanced solid tumors that have a specific protein called Claudin18.2. The main goals are to find a safe dose and see if the drug can help shrink tumors. It will involve about 246 participants whose cancer has not res…